Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Zimmer Biomet Holdings Inc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.28, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while KraneShares Hang Seng TECH Index ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| KTEC | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $19.51 | $107.71 |
52-Week Low | $12.00 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC stock is trading at $13.28, up 2.23% today, showing positive momentum. The stock's technical picture indicates recent strength, though key financial ratios including P/E, P/S, and profitability metrics are currently unavailable for analysis. No recent earnings data or business developments are accessible to provide fundamental context.
Investment outlook remains unclear due to insufficient financial data. The primary opportunity lies in the stock's recent price appreciation, while risks include limited transparency on company fundamentals and the absence of analyst coverage or institutional positioning data to validate current valuation levels.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
